Archean Chemical Industries Q4 FY26 earnings call

Archean Chemical reported a challenging Q4 FY26, with standalone total income decreasing 9% YoY to INR 304.7 crores and EBITDA declining 34.3% YoY to INR 66.4 crores, resulting in an EBITDA margin of 21.79%. For the full year FY26, standalone total revenue grew 2% YoY to INR 1,088.8 crores, but EBITDA and PAT both declined 17% YoY to INR 308 crores and INR 154.3 crores, respectively. Consolidated figures for Q4 FY26 showed total revenue of INR 306.3 crores and PAT of INR 12.2 crores, while full year consolidated revenue was INR 1,108 crores with PAT at INR 105.4 crores.

The company faced significant headwinds in Q4 FY26 due to Kutch road repairs, which increased transportation distance by 2x and led to an estimated INR 14-15 crores increase in logistics costs for the quarter. Industrial fuel prices also surged by nearly 50%. These issues, exacerbated by the Middle East crisis, contributed to a 7.2% YoY decline in Q4 industrial salt volumes and an increase of approximately INR 13 crores in finished salt inventory costs. Management anticipates these road construction challenges to persist until early Q3 FY27.

Despite the volatile environment, the bromine business demonstrated resilience, with Q4 volumes increasing 4% YoY to 3,731 metric tons and realizations improving 14% YoY. Production levels have recovered to historical daily rates of 54-55 tons. The company has successfully renegotiated the majority of its long-term bromine contracts upwards. Management is targeting 15-20% annual growth in bromine production, aiming for 25,000 tons in FY27 and a long-term goal of 40,000 tons, supported by ongoing brine field expansion.

The bromine derivatives segment (Acume) showed strong growth, with Q4 sales up nearly 50% YoY and full-year revenue increasing by almost 300%. However, margins were pressured by lower capacity utilization (around 45%) and challenges related to longer product development cycles for pharma applications, aggressive commercial pricing, and bromine supply issues in prior quarters. To address this, Archean is enhancing sales capabilities, accelerating product development (e.g., launching PBR 3 and scaling zinc bromide), and implementing process optimization initiatives to improve contribution margins starting in early FY27.

Archean's semiconductor subsidiary, SiCSem, achieved a significant milestone by signing a fiscal support agreement with the Government of India for its Odisha project. Design work is currently underway, with substructure construction targeted to commence in July 2026. The project is projected to take 24-30 months from July to reach production, underscoring the company's commitment to long-term opportunities in advanced materials like semiconductors.

The Idealis Mudchemie segment, which includes products like bentonite, barite, starch, and PAC, faced operational delays. The Mandvi bentonite plant, expected to contribute 40-45% of the earlier INR 150 crores revenue guidance, is currently stalled due to pending licenses and approvals from the Gujarat government. Other plants are undergoing product line retooling and customer trials for new products. Management anticipates that at least two out of the three plants will achieve reasonable operational volumes in H2 FY27, despite the sluggishness in the oil and gas market.

Archean's strategic priorities include consolidating its core salt and bromine businesses, scaling up derivatives and oilfield/SOP segments, and investing in advanced materials. The company aims to drive earnings quality, ensure effective capital allocation, and achieve operational excellence through focused growth, customer partnerships, and technology adoption. Management expressed optimism for future demand outlook in their categories and expects a return to historical margin levels once external factors like logistics and commodity costs stabilize.